A detailed history of Vanguard Group Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,705,472 shares of VTYX stock, worth $8.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,705,472
Previous 3,741,925 0.97%
Holding current value
$8.56 Million
Previous $9.24 Million 120.52%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.9 - $10.13 $69,260 - $369,268
-36,453 Reduced 0.97%
3,705,472 $20.4 Million
Q4 2023

Feb 14, 2024

BUY
$2.08 - $31.18 $2.24 Million - $33.7 Million
1,079,254 Added 40.53%
3,741,925 $9.24 Million
Q3 2023

Nov 14, 2023

BUY
$29.8 - $40.3 $8.28 Million - $11.2 Million
277,906 Added 11.65%
2,662,671 $92.5 Million
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $16.5 Million - $22.8 Million
577,060 Added 31.92%
2,384,765 $78.2 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $9.19 Million - $14.5 Million
311,534 Added 20.82%
1,807,705 $60.6 Million
Q4 2022

Feb 10, 2023

BUY
$24.16 - $36.38 $9.48 Million - $14.3 Million
392,218 Added 35.53%
1,496,171 $49.1 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $2.49 Million - $7.62 Million
197,014 Added 21.72%
1,103,953 $38.5 Million
Q2 2022

Aug 12, 2022

BUY
$11.95 - $18.75 $5.14 Million - $8.06 Million
430,077 Added 90.19%
906,939 $11.1 Million
Q1 2022

May 13, 2022

SELL
$10.0 - $19.98 $910 - $1,818
-91 Reduced 0.02%
476,862 $6.47 Million
Q4 2021

Feb 14, 2022

BUY
$14.2 - $23.07 $6.77 Million - $11 Million
476,953 New
476,953 $9.47 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $131M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.